HALO
HALOZYME THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q3 2023 | 11Q | $44 | $67 | +54% |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $55 | $67 | +22% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $57 | $67 | +17% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $57 | $67 | +17% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $57 | $67 | +17% |
| Point72 Asset Management re-entered | Q1 2025(8Q snapshot) | 5Q | $58 | $67 | +16% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management 3× in & out | Q3 2025 | Q1 2026 | — | +0% |
| Two Sigma Investments 2× in & out | Q3 2025 | Q4 2025 | — | +0% |
| Maverick Capital | Q1 2021 | Q3 2021 | → $41 | -16% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at HALOZYME THERAPEUTICS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001159036-26-000074Jun 3, 2026
- Form 40001159036-26-000072Jun 2, 2026
- Form 40001159036-26-000070May 13, 2026
- Form 40001159036-26-000064May 7, 2026
- Form 40001159036-26-000063May 7, 2026
- Form 40001159036-26-000062May 7, 2026
- Form 40001159036-26-000061May 7, 2026
- Form 40001159036-26-000060May 7, 2026
- Form 40001159036-26-000059May 7, 2026
- Form 40001159036-26-000055May 5, 2026
- Form 40001159036-26-000048Apr 7, 2026
- Form 40001159036-26-000047Apr 2, 2026
- Form 40001159036-26-000046Apr 2, 2026
- Form 40001159036-26-000033Mar 10, 2026
- Form 40001159036-26-000032Mar 4, 2026
Fundamentals
XBRL · HALOZYME THERAPEUTICS, INC.Annual figures sourced directly from HALOZYME THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for HALOZYME THERAPEUTICS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 11, 2026
- 8-KMaterial eventMay 11, 2026
- 8-KMaterial eventMay 7, 2026
- 8-KMaterial eventApr 30, 2026
- 8-KMaterial eventApr 24, 2026
- DEF 14AProxy statementMar 23, 2026
- 8-KMaterial eventMar 12, 2026
- 10-KAnnual reportFeb 17, 2026
- 8-KMaterial eventFeb 17, 2026
- 8-KMaterial eventJan 28, 2026
- 8-KMaterial eventDec 9, 2025
- 8-KMaterial eventDec 8, 2025
- 8-KMaterial eventNov 24, 2025
- 8-KMaterial eventNov 12, 2025
- 8-KMaterial eventNov 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $67 | $67 | +0% |
| Citadel Advisors | Q1 2026 | open | $0.00 | — | +0% |
| Point72 Asset Management | Q4 2025 | open | $0.00 | — | +0% |
| Bridgewater Associates | Q4 2025 | open | $71 | $66 | -7% |
| Two Sigma Investments | Q3 2025 | Q4 2025 | $0.00 | — | +0% |
| Millennium Management | Q3 2025 | Q1 2026 | $0.00 | — | +0% |
| Point72 Asset Management | Q3 2025 | open | $0.00 | — | +0% |
| Citadel Advisors | Q2 2025 | Q4 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q1 2025 | Q1 2026 | $58 | $80 | +38% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $58 | $49 | -16% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $57 | $54 | -6% |
| Citadel Advisors | Q3 2024 | open | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | open | $57 | $67 | +17% |
| D.E. Shaw | Q3 2024 | open | $57 | $67 | +17% |
| AQR Capital Management | Q3 2024 | open | $57 | $67 | +17% |
| Millennium Management | Q3 2024 | open | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | open | $57 | $67 | +17% |
| Renaissance Technologies | Q3 2024 | open | $55 | $67 | +22% |
| Bridgewater Associates | Q3 2023 | Q1 2025 | $44 | $59 | +34% |
| Maverick Capital | Q1 2021 | Q3 2021 | $49 | $41 | -16% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.